My next guess is that it's more to determine anti-inflammatory properties of Brilacidin that would make the platform more valuable. With multiple US trials that already show safety, it's likely going to be easy to get approval for the next trial in the US. Which indication moves forward first will likely depend on the final trial results of B-up and B-om. We already have the B-absssi ph 2b results. These other two will paint a clearer picture of what this drug can or can't do. Until then, I don't know which indication they'll move forward on first.
Just like Prurisol showing efficacy on the 200mg arm in the psoriasis trial, it gave the company more options on how to proceed.
It will be interesting to see what partner/s they end up with.
In Reply to 'Scottwny'
Thanks Karin. Will that have any effect on becoming approved in the US?
News 
Market Data 
Discover 
